Two treatments per year as opposed to 12, what’s not to like? In two words—surgical implants. That’s the stigma Genentech will potentially face as it …
Even as Biogen dominates biopharma headlines with its high-profile Aduhelm launch, the company’s budding biosimilar business has been quietly building up—and now, it has another …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
